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nanoliposomes with different surface charges
against Pseudomonas aeruginosa (ATCC 29248)
Amir Gharib1*†, Zohreh Faezizadeh1† and Masoud Godarzee2†Abstract
Background: Pseudomonas aeruginosa exhibits multiple antibiotic resistance mechanisms. Different studies have
shown that entrapment of antibiotics into liposomes could increase their anti-Pseudomonas activity. The objectives
of this study were to prepare ticarcillin loaded-nanoliposomes with variable surface charges and evaluate their
in vitro and in vivo efficacies against Pseudomonas aeruginosa (ATCC 29248).
Methods: Ticarcillin-loaded nanoliposomes with positive, negative and neutral surface charges were prepared by
extrusion method. Ticarcillin encapsulation efficacies for different formulations were measured by HPLC method.
Minimum inhibitory concentration (MIC) of ticarcillin nanoliposomal forms against strain ATCC 29248 were
determined by broth dilution method. The killing rate of Pseudomonas aeruginosa was exposed to various
concentrations of ticarcillin in free and nanoliposomal forms were analyzed. Ultimately, in vivo therapeutic efficacy
of nanoliposomes in burned mice skin infected with strain ATCC 29248 was investigated.
Results: The encapsulation efficacies for ticarcillin-loaded cationic nanoliposomes were significantly higher
(76%± 0.17) than those of neutral (55%± 0.14) and anionic (43%± 0.14) nanoliposomes. The MIC of free, cationic,
neutral and anionic nanoliposomal forms of ticarcillin against ATCC 29248 were to 24, 3, 6 and 48 mg/L,
respectively. The killing rates of ticarcillin-loaded cationic nanoliposomes were higher than those of free and other
drug formulations. Treatment by ticarcillin-loaded nanoliposomes with positive, neutral and negative surface
charges resulted in almost 100, 60 and 20% survival rates, respectively.
Conclusion: Our data suggested that cationic ticarcillin-loaded nanoliposomes because of high effectiveness would
be a good choice to treatment of Pseudomonas aeruginosa infections.
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Pseudomonas aeruginosa is an opportunistic pathogen
causing severe, acute and chronic nosocomial infections
in hospitals, especially burn units [1]. Since P. aerugi-
nosa can rapidly disseminate from the burn wound sites
into the blood stream the clinical outcome in these
patients can lead to sepsis, which is often fatal [2]. The
major problem associated with Pseudomonas infection is
resistance to conventional antibiotics. Therefore, there is* Correspondence: amirgharib@gmail.com
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reproduction in any medium, provided the orthe compelling need to develop novel drug delivery to
overcome this resistance [3]. Ticarcillin is an antibiotic
belonging to the carboxypenicillin subgroup of third-
generation penicillins and covers gram-negative bacteria
such as P. aeruginosa, but nowadays, this drug is suscep-
tible to degradation by P. aeruginosa beta-lactamases
[4,5]. Like other antibiotics, increasing time and usage
have led to resistance to ticarcillin and so, a delivery sys-
tem that reducing the ticarcillin-resistant while increasing
its therapeutic index is of great interest, and nanolipo-
somes can provide these benefits [6,7]. Liposomes are
spherical and colloidal vesicles that may range from a tens
nanometer to several micrometers in size [8,9]. The
alterations of liposomal lipids can lead to production ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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or negatively charged liposomes were obtained using both
phosphatidylcholine and cholesterol, in combination with
stearylamine or dicetylphosphate, respectively [12,13].
Later studies demonstrated that encapsulation of antibio-
tics into liposomal formulations with different surface
charges markedly alters their pharmacokinetics, increas-
ing half-lives and effectiveness [14,15]. Variable results
were reported on the in vitro and in vivo antibacterial
activity of liposomal antibiotics against bacteria [7,9].
While some antibiotics such as amikacin are only slowly
released from the liposomal carrier, other drugs including
ciprofloxacin leak out rapidly [15]. According to the lit-
erature, manipulation of physicochemical characteristics
of liposomes, like particle size, surface charge, sensitivity
to pH changes and bilayer rigidity can have marked
effects on the in vitro and in vivo behavior of antibiotics
loaded liposomes and therefore have a major impact on
therapeutic success [1,7,14]. The effectiveness of
ticarcillin-loaded in nanoliposomes with deferent surface
charges yet was not studied. The primary objective of this
study was to prepare the ticarcillin-loaded nanoliposomes
with three different (neutral, negative and positive) sur-
face charges and evaluate in vitro antibacterial activity of
their against P. aeruginosa (ATCC 29248). A secondary
objective was to investigate the therapeutic efficacy of
prepared nanoliposomes using a mouse burn model.
Methods
Materials
Ticarcillin, stearylamine, dicetylphosphate, cholesterol
and egg lecithin was purchased from Sigma Chemical
Company (St. Louis, USA) and chloroform, methanol,
ammonium acetate and Muller-Hinton broth was pur-
chased from Merck (Darmstadt, Germany).
Microorganism
P. aeruginosa (ATCC 29248) was purchased from
American Type Culture Collection (Rockville, MD,
USA). For experimentation, this strain was inoculated
onto blood agar plates and incubated for 24 h at 37°C.
Preparation of nanoliposomes
Nanoliposomes were prepared by extrusion method as
previously described [16]. Briefly, egg lecithin and choles-
terol in the molar ratio of 4:1 were dissolved in chloro-
form and dried to a lipid film with a rotary evaporator
(Brinkman, Toronto, Canada) under N2 flow and vacuum
at 30°C. The dried lipids were dispersed by agitation in
6 ml of an aqueous solution of ticarcillin (10 mg/ml in
PBS, pH 7.4) and sonicated at 4°C in ultrasonic bath
(Braun-sonic 2000, Burlingame, USA). At finally,
ticarcillin-loaded neutral nanoliposomes were obtained
by extruding of respective suspension through apolycarbonate membrane with 100 nm-sized pores for
12 times and separating excess free drug and larger lipid
aggregation by centrifugation (100000 g for 30 min).
Cationic and anionic ticarcillin-loaded nanoliposomes
were prepared and optimized by added stearylamine
and dicetylphosphate in nanoliposomal membrane for-
mulations in molar ratios of 0.5, 1, 2 and 3, respectively.
Control nanoliposomes were prepared similarly, but
PBS (pH 7.4) was used instead of the ticarcillin solution.
Determination of encapsulation efficacy
The content of ticarcillin in prepared nanoliposomes
was determined by HPLC as described previously [17].
Then, the percentage of drug loading was calculated as:
Amount of ticarcillin in nanoliposomes
 Total volume tested
 100=Total sample volume
 Initial amount of ticarcillin
Particle size, zeta-potential and polydispersity index
determination
Mean particle size, zeta-potential and polydispersity
index of nanoliposomes was evaluated by the reported
method using Malvern zetasizer (Malvern instrument,
Worcestershire, UK) apparatus [11].
Antimicrobial susceptibility testing
The MICs of free and variable ticarcillin-loaded nanolipo-
somes for P. aeruginosa (ATCC 29248) were determined
by the broth dilution technique as recommended by CLSI
(formerly NCCLS) [18]. Bacterial cell suspensions of
~ 5×105 cells/ml were diluted in Muller-Hinton broth
and dispensed (100 μl) into a microtiter tray containing
serial two-fold dilutions of ticarcillin. The tray was then
incubated for 24 h at 37°C. The MIC was recorded to be
the lowest concentrations of ticarcillin in free and nanoli-
posomal forms that prevented visible bacterial growth
and expressed in μg/ml.
Time-kill studies
Time kill studies were preformed in triplicate in 10 ml
tubes containing 2 ml of Mueller-Hinton broth as
described previously [19]. In brief, 100 μl of P. aerugi-
nosa suspension were resuspended in 10 ml of Mueller-
Hinton broth and incubated overnight at 37°C, and
adjusted to a McFarland standard of 0.5. Then, 100 μl of
this standardized inoculum were added to separate cul-
ture tubes containing 1 ml of Mueller-Hinton broth with
1 ml ticarcillin solutions in free and different nanolipo-
somal forms at 1, 2 and 4 times the MIC and incubated
at 37°C. At finally, colony counts were performed onto
Trypticase soy agar (TSA) plates at 0, 2, 4, 6 and 24 h
Table 1 Influence of stearylamine molarity in
encapsulation efficacy*
Molarity of stearylamine
0.5 1 2 3
Encapsulation efficacy 70 ± 0.14 76%± 0.17** 67 ± 0.32 63 ± 0.18
* The Data are expressed as Mean ± S.E.M.
** Significant difference (p < 0.05).
Table 2 Influence of dicetylphosphate molarity in
encapsulation efficacy*
Molarity of dicetylphosphate
0.5 1 2 3
Encapsulation efficacy 38 ± 0.34 43%± 0.14** 34 ± 0.11 27 ± 0.30
* The Data are expressed as Mean ±S.E.M.
** Significant difference (p < 0.05).
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unit (CFU)/ml.
In vivo study
In vivo therapeutic efficacies of ticarcillin-loaded nanoli-
posomes were tested by a described method [20], with
some modification. In brief, sixty male BALB/c mice (20–
22 g) obtained from the National Institute of Pasture,
Iran. Animals were handled according to the national
guidelines of the laboratory animal and housed in separ-
ate and pathogen- free cages and received food and water
ad libitum [21]. All groups were anesthetized with
ketamine-xylazine mixture (50 mg/kg each, given intra-
muscularly), and their backs were shaved. To induce burn
in the backs of mice, a brass bar (10 by 10 by 100 mm)
was heated in boiling water for 15 min and applied on the
shaved back of the animals for 45 s. Then, 50 μl of the
bacterial inoculum (containing 109 CFU of total bacteria)
was applied subcutaneously into the sites of the burn on
the animal’s back. The mice were divided into 5 groups.
All groups were treated topically as follows: Group 1
received cationic ticarcillin-loaded nanoliposomes (75 mg/
kg/12h); group 2 received neutral ticarcillin-loaded nanoli-
posomes (75 mg/kg/12h); group 3 received anionic
ticarcillin-loaded nanoliposomes (75 mg/kg/12h); group 4
received anionic ticarcillin-loaded nanoliposomes (75 mg/
kg/12h); group 5 received empty nanoliposomes (75 mg/
kg/12h), and group 6 received physiological saline (1 ml/
kg/12h); for 7 days starting from the 3rd day post infec-
tion. Two days after the last dose the surviving animals
were anesthetized and sacrificed by cervical dislocation
and the liver, kidney, spleen and skin of mice were
removed under sterile conditions and homogenized for 5–
10 min in PBS (2 ml/g). The homogenates were serially
diluted and plated for growth in TSA. The inoculated
plates were then incubated at 37°C for 24 h and the colony
forming unit (CFU) was counted.
Data analysis
The results were expressed as means  standard errors
of means. The data of killing rate study were statistically
evaluated by paired Student’s t-test, and P value of less
than 0.05 was considered significant. The survival rates
of control and treated mice were determined by using
chi-squared with Yates correction and by Fisher’s exact
test. Therefore, these data were used to prepare of cat-
ionic and anionic ticarcillin-loaded nanoliposomes.
Results
Encapsulation efficacy
The results showed that encapsulation efficacies of ticar-
cillin in cationic, neutral and anionic nanoliposomal
forms were 76%± 0.17, 55%± 0.21 and 43%± 0.14, re-
spectively. Tables 1 and 2 shows the highestencapsulation efficacies of ticarcillin into cationic and
anionic nanoliposomes were obtained by the addition of
1 molar of stearylamine and dicetylphosphate to formu-
lations, respectively.Particle size, zeta-potential and polydispersity index
analysis
Table 3 shows the mean particle size, zeta-potential and
polydispersity index of empty and ticarcillin loaded-
nanoliposomes with variable surface charges. Size homo-
geneity of empty and loaded-nanoliposomes suggested
that ticarcillin was entrapped into lipid bilayer, according
to the previous studies [14,21]. Zeta-potential of
nanoliposomes revealed that prepared nanoparticles
have appropriate stability in aqueous dispersion [22].Bacterial susceptibilities
The MICs values ticarcillin in either free or nanoliposo-
mal forms for P.aeruginosa (ATCC 29248) was shown in
Table 4. The MICs of free, cationic and neutral nanoli-
posomal forms of ticarcillin were higher than anionic
formulation, respectively.Time-killing study
The killing curves of ticarcillin in free and encapsulated
forms at 1, 2 and 4 times the MICs was shown in Figure 1.
In all conditions free ticarcillin was more effective on
reduced bacterial counts as compared with ticarcillin
encapsulated in anionic nanoliposomes (Figure 1). At one
times of MIC only ticarcillin encapsulated in cationic
nanoliposomes could eliminate of P. aeruginosa after 24 h
(Figure 1-A). At two times of MIC both ticarcillin encap-
sulated in cationic and neutral nanoliposomes eradicated
the bacteria after 6 and 24 h, respectively (Figure 1-B). At
four times of MIC, both ticarcillin in free and encapsu-
lated in cationic and neutral nanoliposomes could
Table 3 Particle size, zeta-potential and polydispersity index of empty and ticarcillin-loaded nanoliposomes
Formulations Mean particle size (nm) Zeta-potential (mV) Polydispersity index
Empty
Neutral liposomes 94.9 ± 0.15 −1.1 ± 0.27 0.22 ± 0.01
Anionic liposomes 93.2 ± 0.36 −15.7 ± 0.95 0.23 ± 0.04
Cationic liposomes 95.3 ± 0.49 +20.1 ± 0.52 0.25 ± 0.02
Loaded
Neutral liposomes 95.2 ± 0.31 −1.1 ± 0.27 0.23 ± 0.02
Anionic liposomes 92.6 ± 0.44 −15.2 ± 0.86 0.26 ± 0.01
Cationic liposomes 96.1 ± 0.14 +21.8 ± 0.13 0.25 ± 0.03
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24 h, respectively (Figure 1-C).
Therapeutic efficacy test
The treatment of the P. aeruginosa-infected burned mice
with ticarcillin-loaded cationic nanoliposomes compared
to control animals showed significant reduction in CFU
values in evaluated organs, especially in skin, spleen and
liver (Table 5). It was found that mortality of mice as
control (without AmB administrated) was 100% after
7 days, whereas mice treated with ticarcillin in free and
encapsulated in cationic, neutral and anionic nanolipo-
somes showed the increase in survival rate of 30, 100, 60
and 20%, respectively.
Discussion
The use of liposomes as antibiotic carrier systems has
been widely investigated [11,20]. However, the main pro-
blems associated with application of liposomes as car-
riers for antibiotics is insufficient quantities in the target
site [1,18]. In addition, the preparation of antibiotic-
loaded liposomes with high encapsulation efficacy may
not be easy because the variable interactions between
antibiotics and bilayer lipids can occur [2,11]. For the
elimination of this problem, investigators were changed
lipids in liposomal membrane formulation. In this re-
port, we evaluated the potential of incorporation of
ticarcillin into cationic, neutral and anionic nanolipo-
somes. The results showed that ticarcillin can be encap-
sulated into three kinds of nanoliposomes with variableTable 4 In vitro antimicrobial activities of free and
nanoliposomal forms of ticarcillin for P. aeruginosa (ATCC
29248)
Minimum inhibitory concentration (mg/L)






24 3 6 48entrapment efficacy. It has been shown that the highest
encapsulation efficiencies occur when lipids and loaded
drugs have opposite charges [13,15]. In this case, we pre-
viously reported that superoxide dismutase (SOD) with
negative surface charge has high encapsulation efficacy
in cationic liposomes [12]. Whereas the electric charge
of ticarcillin in the pH 7.4 is negative [20], it probably
makes the encapsulation efficacy of ticarcillin in cationic
nanoliposomes were higher than neutral and anionic
nanoliposomes, respectively. Our results suggest that en-
trapped of ticarcillin in neutral and cationic nanoliposo-
mal forms enhanced the antipseudomonal activity of its
compared to free ticarcillin. Our data fits well with some
other studies. We previously studied that amikacin-
loaded neutral liposomes displayed stronger bactericidal
activity than the free drug [9]. Furthermore, it has been
reported that encapsulated of cephalexin in liposomes
with neutral and negative surface charges could protect
the drug from hydrolysis by staphylococcal β-lactamase
as well [22]. Several hypotheses, including increased
electrostatic impulsion and protection of the antibiotics
from bacterial enzymes may explain the mechanism of
enhanced antimicrobial activities of liposomal formula-
tions [7,14,23]. Additionally, the molecular configuration
of antibiotics within liposomes could play an important
role in these cases [18]. The time-kill assays confirmed
that higher potency of cationic and neutral nanoliposo-
mal forms of ticarcillin than free antibiotics. These
results are in accordance with previous findings, which
reported that a significantly higher killing rate of P. aer-
uginosa with meropenem and gentamicin-loaded cat-
ionic liposomes were occurred [24]. So, we hypothesized
that electrostatic interaction between the outer mem-
brane lipopolysaccharides of P. aeruginosa and cationic
nanoliposome loaded-ticarcillin could enhance the
mechanism of drug entry into this microorganism cell.
Burns, wounds, and other exposed tissues are particu-
larly susceptible to microbial contamination and infec-
tions [25,26]. It is proven that potential mortality from
burn wound infections, even with aggressive antibiotic
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Figure 1 Killing curves for P. aeruginosa (ATCC 29248) was exposed to various concentrations (A=1×MIC, B=2×MIC and C=4×MIC) of
ticarcillin in free and neutral, negative and positive nanoliposomal forms. *Significant difference between killing rate of empty
nanoliposomes versus free and another loaded nanoliposomes (p<0.01), **Significant difference between killing rate of cationic nanoliposomes
versus free and another loaded nanoliposomes (p<0.05), ***Significant difference between killing rate of cationic nanoliposomes versus free and
another loaded nanoliposomes (p<0.01), +Significant difference between killing rate of neutral nanoliposomes versus free and anionic
nanoliposomes (p<0.05), ++Significant difference between killing rate of free drug versus anionic nanoliposomes (p<0.05). +++Significant difference
between killing rate of cationic nanoliposomes versus free and another loaded nanoliposomes (p<0.01).
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resulted in 100% survival rate and in almost complete
eradication of the bacteria from the spleens, livers, and
skins of infected animals. These results may be due to
the optimal antibiotic delivery that reported by several
investigators [20,28]. When cationic liposomes contain-
ing antibiotics are applied topically; they may interact
with the cell membranes of exposed tissues andtherefore, protects the burn wound tissues from further
bacterial contamination [29].
Conclusion
In vitro and in vivo testing of nanoliposomes indicated
that ticarcillin-loaded in cationic nanoliposomes have a
stronger protective effect against P. aeruginosa infection
compared to free, neutral and anionic ticarcillin
Table 5 The survival rate of infected burned mice and colony-forming units (CFUs) of P. aeruginosa (ATCC 29248) in
different organs
Treatment Tissue/Organ Log CFU/ Gram tissue (n=3) Percentage of survival mice (n=10)
Control without drug administration
(received physiological saline, Topically)
Liver 3.211 ± 0.5 None survived
Kidney 3.750 ± 0.3
Spleen 3.829 ± 0.6
Skin 3.690 ± 0.2
Empty nanoliposomes (1 mg Kg-1, Topically) Liver 3.355 ± 0.4 None survived
Kidney 3.960 ± 0.8
Spleen 3.764 ± 1.5
Skin 3.590 ± 1.3
Free ticarcillin (1 mg Kg-1, Topically) Liver 2.315 ± 0.04 30
Kidney 2.198 ± 0.07
Spleen 2.312 ± 1.3
Skin 2.420 ± 0.04
Anionic ticarcillin-loaded nanoliposome
(1 mg Kg-1, Topically)
Liver 2.715 ± 0.8 20
Kidney 2.910 ± 0.2
Spleen 2.650 ± 1.4
Skin 2.680 ± 1.1
Neutral ticarcillin-loaded nanoliposome
(1 mg Kg-1, Topically)
Liver 1.712 ± 0.6 60
Kidney 2.045 ± 0.1
Spleen 1.024 ± 1.1
Skin 1.362 ± 0.04
Cationic ticarcillin-loaded nanoliposome
(1 mg Kg-1, Topically)
Liver Nil* 100
Kidney 1.013 ± 0.07**
Spleen Nil*
Skin Nil*
The Data are expressed as Mean±Standard error of mean from three separate experiments. Analysis of variance of one-way classification between the treatment
means was heterogeneous and the t-test values (two-tailed) were significant, * p <0.001 and ** p < 0.05.
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lations would be a good choice for treatment of patients
with P. aeruginosa infections, especially in burn units of
hospitals.
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